Short Interest in Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) Rises By 117.6%

Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI) was the recipient of a significant growth in short interest in March. As of March 15th, there was short interest totalling 3,700 shares, a growth of 117.6% from the February 28th total of 1,700 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 10,700 shares, the short-interest ratio is presently 0.3 days.

Scinai Immunotherapeutics Stock Down 3.4 %

Shares of SCNI opened at $2.80 on Friday. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.06. The company has a 50-day moving average price of $3.41 and a two-hundred day moving average price of $3.45. The stock has a market cap of $2.62 million, a price-to-earnings ratio of -0.01 and a beta of 2.36. Scinai Immunotherapeutics has a 12 month low of $2.23 and a 12 month high of $8.92.

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.